Chromosome copy number changes carry prognostic information independent of KIT/PDGFRA point mutations in gastrointestinal stromal tumors by Mara Silva et al.
Silva et al. BMC Medicine 2010, 8:26
http://www.biomedcentral.com/1741-7015/8/26
Open AccessR E S E A R C H  A R T I C L EResearch articleChromosome copy number changes carry 
prognostic information independent of 
KIT/PDGFRA point mutations in gastrointestinal 
stromal tumors
Mara Silva1, Isabel Veiga1, Franclim R Ribeiro1, Joana Vieira1, Carla Pinto1, Manuela Pinheiro1, Bárbara Mesquita1, 
Catarina Santos1, Marta Soares2, José Dinis2, Lúcio Santos3, Paula Lopes4, Mariana Afonso4, Carlos Lopes4 and 
Manuel R Teixeira*1,5
Abstract
Background: Oncogenic point mutations in KIT or PDGFRA are recognized as the primary events responsible for the 
pathogenesis of most gastrointestinal stromal tumors (GIST), but additional genomic alterations are frequent and 
presumably required for tumor progression. The relative contribution of such alterations for the biology and clinical 
behavior of GIST, however, remains elusive.
Methods: In the present study, somatic mutations in KIT and PDGFRA were evaluated by direct sequencing analysis in a 
consecutive series of 80 GIST patients. For a subset of 29 tumors, comparative genomic hybridization was additionally 
used to screen for chromosome copy number aberrations. Genotype and genomic findings were cross-tabulated and 
compared with available clinical and follow-up data.
Results: We report an overall mutation frequency of 87.5%, with 76.25% of the tumors showing alterations in KIT and 
11.25% in PDGFRA. Secondary KIT mutations were additionally found in two of four samples obtained after imatinib 
treatment. Chromosomal imbalances were detected in 25 out of 29 tumors (86%), namely losses at 14q (88% of 
abnormal cases), 22q (44%), 1p (44%), and 15q (36%), and gains at 1q (16%) and 12q (20%). In addition to clinico-
pathological high-risk groups, patients with KIT mutations, genomic complexity, genomic gains and deletions at either 
1p or 22q showed a significantly shorter disease-free survival. Furthermore, genomic complexity was the best predictor 
of disease progression in multivariate analysis.
Conclusions: In addition to KIT/PDGFRA mutational status, our findings indicate that secondary chromosomal changes 
contribute significantly to tumor development and progression of GIST and that genomic complexity carries 
independent prognostic value that complements clinico-pathological and genotype information.
Background
Gastrointestinal stromal tumors (GIST) represent the
most common mesenchymal tumors of the gastrointesti-
nal tract [1]. A diagnosis of GIST involves a multidisci-
plinary approach that combines clinical, pathological,
and genetic features. Mutually exclusive activating muta-
tions in KIT or PDGFRA occur in 85 to 90% of the cases
and are considered primary events in GIST pathogenesis
[1-3]. These genes encode type III transmembrane recep-
tor proteins which, upon connection to their respective
ligands, activate downstream signaling pathways involved
in cell proliferation and survival [4-6].
Whereas oncogenic KIT or PDGFRA mutations seem
vital to promote the neoplastic transformation, additional
somatic alterations are presumably necessary for the bio-
logical and clinical progression of these tumors and may
explain the different responses to targeted therapy seen in
these patients. Genome-screening methodologies, such
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hybridization (CGH), have been applied in order to iden-
tify these changes. Some chromosomal alterations, such
as losses at 1p, 14q, and 22q, are particularly frequent,
suggesting the existence of tumor suppressor genes in
these regions that could be important in tumor progres-
sion [7-10]. Although this cytogenetic fingerprint of
GIST has been defined, the target genes involved in these
regions remain undiscovered [11]. Furthermore, the rela-
tionship between the pattern of KIT and PDGFRA onco-
genic mutations and that of cytogenetic changes has not
been systematically studied, precluding a full understand-
ing of the genetic pathways involved in GIST develop-
ment.
In this work, we assessed the genetic background of a
consecutive series of 80 patients diagnosed with GIST.
KIT or PDGFRA mutations were evaluated in all samples
using direct sequencing analysis. For a subset of 29
patients with fresh-frozen tisue, CGH was used to screen
for chromosomal copy number aberrations. Cytogenetic
and molecular genetic findings were integrated and cor-




A series of 80 patients diagnosed with GIST and submit-
ted to surgery with curative intent were included in this
study. The majority of patients was diagnosed and treated
at the Portuguese Oncology Institute - Porto, with the
exception of six cases that were provided by other institu-
tions. Patients had received no treatment prior to surgery.
Fresh-frozen tumor samples from 29 patients were avail-
able for mutational and CGH analyses, whereas for the
remaining cases mutational analyses were performed in
formalin-fixed, paraffin-embedded tissue sections. In all
cases, hematoxylin and eosin stained sections from repre-
sentative tissue blocks were reviewed by expert patholo-
gists to confirm a diagnosis of GIST and to evaluate
relevant histopathological parameters. Immunohis-
tochemistry for CD117 followed the standard avidin-bio-
tin-peroxidase complex method with a commercial
polyclonal antibody at a 1/600 dilution (A4502, Dako,
Glostrup, Denmark). Other clinical and demographic
variables, such as age at diagnosis, gender, tumor size,
and tumor location (divided into stomach, small intes-
tine, rectum and colon, and outside the GI tract), were
obtained Additional file 1. Patients with tumors that
eventually recurred or that developed metastatic lesions
(n = 36) were treated with imatinib in accordance with
the guidelines followed at the IPO-Porto. Second-line
therapy for patients that progressed or were intolerant to
imatinib (n = 2) was sunitinib. This study was approved
by the institutional review board and was performed in
accordance with national regulations (law 12/2005).
KIT and PDGFRA mutation screening
DNA isolation from formalin-fixed, paraffin-embedded
tumor samples and from physically disaggregated fresh-
frozen tissue fragments was performed using an adapta-
tion of the technique described by Lungu and colleagues
[12] or a salting-out-chloroform mixed methodology
[13], respectively. Using the DNA extracted from each
sample, KIT (exons 9, 11, 13, and 17) and PDGFRA (exons
12, 14, and 18) target sequences were amplified by poly-
merase chain reaction (PCR) on a standard termocycler.
Primers and conditions were as described in the literature
[14,15]. Direct sequencing was performed on an ABI
PRISM 310 automatic sequencer using the Big Dye Ter-
minator Chemistry (Applied Biosystems, Foster City, CA,
USA), according to the manufacturer's recommenda-
tions. All results were confirmed with a second indepen-
dent analysis.
Comparative genomic hybridization
Fresh-frozen tumor samples from 29 patients were ana-
lyzed by CGH following the procedure of Kallioniemi et
al. [16], with modifications previously described [17].
Samples were analyzed with a Cohu 4900 CCD camera
using an automated filter wheel coupled to a Zeiss Axio-
plan fluorescence microscope (Zeiss, Oberkochen, Ger-
many) and a Citovysion system version 3.9 (Applied
Imaging, Santa Clara, CA, USA). For each sample, data
from 10 cells were combined to generate average ratio
profiles with 99% confidence intervals and aberrations
were scored whenever the sample profile and the stan-
dard reference profile at 99% did not overlap [18].
Description of the CGH copy number changes followed
the guidelines suggested by the International System for
Human Cytogenetic Nomenclature (ISCN) 2005 [19].
Statistical analysis
Relevant clinico-pathological (gender, age, tumor size,
tumor location and patient risk groups) and genetic
(mutation status and chromosomal imbalances) variables
were cross-tabulated and analyzed using the chi-square
or Fisher's exact test. The number of chromosomal aber-
rations was compared within groups of samples with dif-
ferent mutation genotypes using the non-parametric
Mann-Whitney U test. Kaplan-Meyer survival curves
using log-rank test were computed for relevant clinical
and genetic events. For statistical purposes, patients with
recurrent or metastatic lesions were included in the high-
risk group. A P-value lower than 0.05 was considered sta-
tistically significant. All analysis was performed using the
Statistical Package for Social Sciences (SPSS) software,
version 15 (SPSS Inc., Chicago, IL, USA).
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Clinicopathologic characteristics of the patients
A total of 80 patients diagnosed with GIST were enrolled
in this study. Tumor location was obtainable in 79 cases,
of which 67 corresponded to primary lesions Additional
file 1. Twelve recurrent or metastatic lesions were ana-
lyzed due to lack of the primary sample. For four of the
patients, a second sample collected after disease progres-
sion could additionally be assessed, increasing the num-
ber of lesions submitted to sequencing analysis to 84.
Tumor size was recorded in 70 cases and varied from 1.2
to 45 cm (average 8.8 cm). From the available morphol-
ogy data, the series included 52 spindle cell tumors, 6 epi-
thelioid lesions, and 13 mixed tumors. Based on the
National Comprehensive Cancer Network taskforce
guidelines for GIST risk assessment [20], most tumors in
this series could be classified as either low/very low risk
(n = 27), moderate risk (n = 8), or high risk (n = 27).
Expression of the KIT protein (CD117) was assessed in 74
cases. A total of 70 lesions (94.6%) showed a positive
staining pattern, whereas two cases were negative and
two cases presented inconclusive findings.
KIT and PDGFRA mutations
Samples from all 80 patients were screened for mutations
within exons 9, 11, 13, and 17 of the oncogene KIT. Muta-
tions were detected in 61 tumors (76.25%, Figure 1),
namely in exon 11 (n = 52), exon 9 (n = 7) and exon 17 (n
= 2). The two patients with KIT exon 17 mutation were
subsequently found to be relatives and the mutation
shown to be present in the germline [21]. No primary
mutations were found in exon 13. All KIT negative cases
(n = 19) were then analyzed for mutations in exons 12, 14,
and 18 of PDGFRA. A total of nine samples (11.25%)
showed mutations in this gene, namely in exon 18 (n = 6),
exon 12 (n = 2), and exon 14 (n = 1). CD117 staining was
seen in six out of eight PDGFRA positive cases. The over-
all mutation frequency for both genes in this series was
87.5% (70 out of 80 tumors). Of note, two tumors with
KIT exon 11 primary mutations and with an initial
response to imatinib, acquired resistance and developed
peritoneal or hepatic metastases that presented the same
secondary mutation (KIT exon 13, p.Val654Glu). A com-
plete description of the mutations and relevant clinical
parameters for each patient are detailed in Additional file
1.
Chromosome copy number changes
Out of the 29 GIST submitted to whole-genome screen-
ing, 25 (86%) displayed copy number changes (Figure 2,
Additional file 2). Most abnormal samples displayed non-
complex profiles, with a median of three aberrations per
tumor (ranging from one to 28 changes), and losses were
1.5 times more frequent than gains. It is noteworthy that
complete or partial loss of 14q was seen in 22 samples
(88%), being the sole copy number change in four
patients. Other frequent changes included losses at 22q
(44%), 1p (44%), and 15q (36%) and gains at 1q (16%) and
12q (20%). All 25 cytogenetically abnormal GIST pre-
sented at least one of the losses 1p, 14q, or 22q.
Integrative analysis of molecular and cytogenetic 
alterations
Based on previous literature findings, samples submitted
to CGH analysis were divided according to mutation gen-
Figure 1 Mutation profile of KIT and PDGFRA in 80 GIST. a) mutation frequency per gene; b) mutation frequency per PDGFRA exon; c) mutation 
frequency per KIT exon. Two patients with primary mutations in KIT exon 11 acquired the same secondary mutation in KIT exon 13 after imatinib treat-
ment. The two patients with KIT exon 17 mutation belong to a family with hereditary GIST, with the mutation being found also in the germline.
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were compared between samples with KIT exon 9 muta-
tions (n = 3), KIT exon 11 deletions/delins (n = 8) or sam-
ples with no detectable mutations (n = 1), totaling 12
cases associated in the literature with bad prognosis, ver-
sus samples with KIT or PDGFRA mutations not previ-
ously associated with a worse prognosis (n = 13).
Strikingly, the former group showed significantly more
copy number changes than the latter (median of 6.5 ver-
sus 2 aberrations per tumor, P = 0.026, Mann-Whitney U
test). The three cases with KIT exon 9 mutations showed
the most complex CGH profiles (median of nine aberra-
tions per tumor), followed by those with exon 11 dele-
tions/delins (median of four aberrations per tumor). It is
noteworthy that three of the four cases without detect-
able CGH alterations showed no mutations in either KIT
or PDGFRA. No significant associations were observed
between specific copy number changes and different
mutation subgroups. Tumors with PDGFRA mutations
showed the same overall pattern of alterations seen in
those with KIT mutations, even if genomic complexity
was much lower in the former (median of 2 vs. 5.5 altera-
tions per tumor, respectively, P = 0.050, Mann-Whitney
U test).
Therapeutic correlations and survival data
Follow-up data was available in 74 cases (median of 30
months, ranging from 8 to 123 months). During this
period, 26 patients (35%) showed disease progression and
were subsequently treated with imatinib. According with
the most recent clinical records, six of these patients died
from their cancer. Most of the samples from the progres-
sion group showed KIT mutations, namely in exon 11 (n
= 21) and exon 9 (n = 3), with only two patients showing
no mutations in either gene. The 48 patients that received
no adjuvant therapy are currently alive without evidence
of disease, with the exception of three non disease-related
deaths. Within this group, 41 tumors harbored muta-
tions, namely in KIT exon 11 (n = 28), KIT exon 9 (n = 4),
PDGFRA exon 12 (n = 2), PDGFRA exon 14 (n = 1), and
PDGFRA exon 18 (n = 6).
Disease-specific survival curves were uninformative
due to the reduced number of death-from-disease events,
and five-year disease-free survival curves were thus com-
puted (Figures 3 and 4, Additional file 3). Stratification
according to tumor location showed that lesions in the
stomach progressed much less frequently than those in
other locations (P < 0.001, Figure 3a). Regarding risk
groups, most progression events were seen in lesions cat-
egorized as high risk (P = 0.001, Figure 3b). When
patients were categorized based on genetic variables, a
more aggressive outcome was seen in patients with KIT
mutations compared to those with PDGFRA mutations
(P = 0.039, Figure 4a). Based on previous literature
reports, patients were additionally categorized according
to specific mutations associated with worse prognosis.
Patients with KIT exon 9 or KIT exon 11 deletions/delins
Figure 2 Copy number profile of patients diagnosed with GIST. Gains and losses of genetic material are depicted along all chromosomes (X axis).
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free survival (P = 0.091) than those showing mutations in
PDGFRA or other mutations in KIT (n = 33 cases).
Within the subgroup of patients with KIT exon 11 muta-
tions, the number of progression events in tumors with
deletions/delins was significantly higher than those with
other mutations (P = 0.003, Fisher's test). In multivariate
analysis including risk groups and genotype (KIT vs PDG-
FRA mutations), a high risk at diagnosis was the strongest
predictor of relapse (HR = 9.8, P = 0.003, 95% CI = 2.2 to
43.1) (Additional file 4: Supplementary Table 4a)
In the subgroup of patients with CGH data and com-
plete follow-up information (n = 27), genomic complexity
was very strongly associated with a worse outcome (P =
0.002, Figure 4b). The presence of genomic gains (P =
0.006) or deletions at 1p or 22q (P = 0.030) were also sig-
nificantly associated with a shorter progression-free
period (Figure 4c and 4d, Additional file 3). Multivariate
survival analysis in this subset (using risk groups, geno-
type status, genomic gains and losses at 1p or 22q)
showed that the best predictor of progression was
genomic complexity (HR = 13.7, P = 0.014, 95% CI = 1.7
to 111.1, Additional file 4: Supplementary Table 4b).
Discussion
Recent years have seen important breakthroughs that
resulted in better diagnostic, prognostic and therapeutic
tools for patients with GIST. Identification of a distinctive
molecular signature involving KIT or PDGFRA mutations
allowed targeted therapies in patients with metastatic dis-
ease, who did not have effective therapeutic options until
then. However, additional genomic changes are known to
occur in GIST that might influence therapy response and
tumor aggressiveness. In the current work, we character-
ized the mutation profile of KIT and PDFGRA in a con-
secutive series of GIST diagnosed and followed at our
institution. Gross genomic aberrations were additionally
assessed in a subset of these patients, in order to deter-
mine the relative contribution of primary and secondary
genetic events in GIST as prognostic or/and predictive
factors.
Tumor size and mitotic index have been considered the
most important prognostic indicators in GIST [22,23].
However, it has been shown that even small GIST can
behave aggressively and develop metastases. Indeed, one
patient with an intestinal lesion with less than 2 cm and
low mitotic rate (patient 20, categorized in the low-risk
group) developed metastases and died from the disease
11 months after diagnosis. More recently, anatomic loca-
tion was also considered of relevance and included in the
determination of the risk of recurrence and progression
[21,24]. Our findings strongly support this prediction
model, as a significant proportion of small intestine or
colon GIST developed metastasis, whereas most tumors
located in the stomach showed no progression events.
KIT and PDGFRA activating mutations are mutually
exclusive events in GIST that promote the constitutive
activation of the receptors and the downstream signaling
pathways, resulting in aberrant cell proliferation and
apoptosis [2]. The overall frequency of KIT and PDGFRA
mutations in GIST varies in different studies, but is usu-
ally higher than 80% [25]. In our 80 samples, we obtained
a mutation frequency of 87.2%, with 75.7% of the cases
harboring KIT mutations and 11.5% showing PDGFRA
mutations, which is significantly higher than the 63%
recently found in a second Portuguese series of GIST [26]
and that of another Iberian Peninsula series [27]. It has
been suggested that the type and molecular location of
different mutational events in GIST carry distinct biolog-
Figure 3 Five-year disease-free survival curves based on selected 
clinical variables. a) Tumor location; b) Risk groups.
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extracellular regulatory domain, coded by exon 9, seem to
mimic the conformational changes that follow stem-cell
factor (SCF) ligation. The most common mutation found
within this location (p.Ala502_Tyr503dup) corresponds
to an insertion of six nucleotides [29], and indeed all our
tumors with exon 9 mutations displayed this hot-spot
alteration. The major mutational hotspot in KIT is in
exon 11, which encodes the juxtamembrane intracellular
domain responsible for modulating KIT enzymatic activ-
ity [24]. KIT exon 11 deletions have been linked to an
aggressive behavior comparing missense and insertion
mutations [27,28,30,31]. In our series, 26 out of 52 muta-
tions in this domain corresponded to deletions/delins.
Interestingly, 15 of these 26 patients showed disease pro-
gression, whereas only four patients in the group with
insertions, duplications or missense mutations showed
disease progression (P = 0.003). It is noteworthy that in
two patients with primary KIT exon 11 mutations treated
with imatinib and in whom additional metastases devel-
oped, the same secondary mutation in KIT exon 13
(p.Val654Glu), known to confer imatinib resistance [32],
was detected. Finally, the two patients in which we identi-
fied the same KIT exon 17 mutation were recently found
to be relatives. In fact, we were able to show that the
p.Asp820Tyr was present also in the germline, represent-
Figure 4 Five-year disease-free survival based on selected genetic variables. a) Mutated gene; b) genomic complexity; c) genomic gains; d) 1p 
or 22q deletions.
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caused by this same mutation [21].
GIST harboring PDGFRA mutations share many clini-
cal features with KIT mutated tumors, but are mainly
gastric and present weak or negative CD117 staining [33].
Existent evidence suggests that PDGFRA mutated tumors
might be less aggressive [34]. Of the nine cases with PDG-
FRA mutations in our series, three showed weak or only
focal CD117 staining, seven were located in the stomach,
and all patients are currently alive with no evidence of
disease. Interestingly, the hotspot p.Asp842Val mutation,
which has been associated with primary resistance to
imatinib [3], was detected in four of these cases. How-
ever, these four patients were classified in the low risk
group and showed no signs of progression thus far. As
such, they have not been submitted to imatinib treat-
ment.
In addition to the primary mutation events activating
KIT or PDGFRA, cytogenetic studies have shown addi-
tional changes associated with GIST progression
[7,35,36]. However, few studies so far have performed
genotype and genome analysis in the same samples, pre-
venting a reliable assessment of correlations between pri-
mary and secondary genetic events, or their combined
prognostic/predictive value [37-39]. In our work, 86% of
the GIST submitted to CGH analysis displayed copy
number changes. Complete or partial deletions of chro-
mosome 14 were seen in 88% of the abnormal cases, and
in four patients this was the sole chromosomal change
detected. Additional recurrent cytogenetic aberrations
included losses at 22q, 1p, and 15q, as well as gains at 1q
and 12q. Genomic complexity (three or more aberrations
per tumor), the presence of gains, deletions at 1p, and
deletions at 22q were associated with a shorter disease-
free survival in this subset of patients, with multivariate
analysis evidencing genomic complexity as the best pre-
dictor of disease relapse. Strikingly, tumors harboring
KIT mutations associated with a bad prognosis showed
significantly more chromosome copy number changes
than those without such mutations. On the opposite side,
tumors with PDGFRA mutations showed the same over-
all pattern of alterations seen in those with KIT muta-
tions, but the complexity was much lower and no
progression events were observed.
Conclusions
Taken together, our findings suggest that secondary chro-
mosome changes have independent prognostic value in
GIST. Furthermore, chromosome level information
might also be useful for differential diagnosis, as the pat-
tern of genomic losses of 1p, 14q, and/or 22q is rather
characteristic. Additional integrative molecular and cyto-
genetic studies are necessary to assess the combined
diagnostic, prognostic, and predictive value of the several
recurrent genetic features of GIST.
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